RAD23 nucleotide excision repair protein AGenealiases: HHR23A · HR23A
Q-omics provides the consensus-scored RAD23A profile across patient tissues and cancer cell-line models. RAD23A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RAD23A is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RAD23A protein abundance shows 23,049 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, KIRC, and PDAC as cancer lineages where RAD23A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAD23A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAD23A survival associations across molecular data types. RAD23A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAD23A RNA expression–survival associations across cancer types. High RAD23A expression shows unfavorable associations in KIRP, LUAD, BLCA, ACC, KICH and LAML. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RAD23A RNA expression.
This table summarizes RAD23A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAD23A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAD23A shows higher tumor expression in KIRC, HNSC, KIRP, COAD, LIHC and LUSC. The KIRC box plot shows higher RAD23A RNA expression in tumor versus normal tissue (log2 FC = +0.901, t-test p < 0.001).
This table shows molecular features associated with RAD23A in patient tissues and cancer cell lines. In patient samples, RAD23A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAD23A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
